Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | CMA1 | P23946 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683520 | 0.93 | CMA1 (0.55) | SLC6A2CMA1ACE | |
| SCHEMBL11271096 | 0.93 | CMA1 (0.55) | SLC6A2CMA1ACE | |
| SCHEMBL683525 | 0.91 | CMA1 (0.48) | SLC6A2OPRM1CMA1ACEOPRD1 | |
| SCHEMBL11282561 | 0.90 | SLC6A2 (0.56) | SLC6A2OPRM1CMA1ACEOPRD1 | |
| SCHEMBL683119 | 0.90 | SLC6A2 (0.56) | SLC6A2OPRM1CMA1ACEOPRD1 | |
| SCHEMBL683073 | 0.89 | SLC6A2 (0.54) | SLC6A2OPRM1CMA1ACEOPRD1 | |
| SCHEMBL683447 | 0.89 | SLC6A2 (0.53) | SLC6A2OPRM1ACENTSR2NTSR1 | |
| SCHEMBL683814 | 0.87 | SLC6A2 (0.56) | SLC6A2OPRM1ACE | |
| SCHEMBL11276961 | 0.84 | CMA1 (0.54) | CMA1ACE | |
| SCHEMBL11287472 | 0.83 | KMT2A (0.50) | CMA1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | SLC6A2 280/4885OPRM1 924/4885CMA1 4710/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | SLC6A2 376/4885OPRM1 1443/4885CMA1 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.